168 related articles for article (PubMed ID: 26906083)
1. Doxorubicin-Loaded Nanobubbles Combined with Extracorporeal Shock Waves: Basis for a New Drug Delivery Tool in Anaplastic Thyroid Cancer.
Marano F; Argenziano M; Frairia R; Adamini A; Bosco O; Rinella L; Fortunati N; Cavalli R; Catalano MG
Thyroid; 2016 May; 26(5):705-16. PubMed ID: 26906083
[TBL] [Abstract][Full Text] [Related]
2. Combining doxorubicin-nanobubbles and shockwaves for anaplastic thyroid cancer treatment: preclinical study in a xenograft mouse model.
Marano F; Frairia R; Rinella L; Argenziano M; Bussolati B; Grange C; Mastrocola R; Castellano I; Berta L; Cavalli R; Catalano MG
Endocr Relat Cancer; 2017 Jun; 24(6):275-286. PubMed ID: 28487350
[TBL] [Abstract][Full Text] [Related]
3. Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.
Wang W; Zhou J; Zhao L; Chen S
Biomed Pharmacother; 2017 Apr; 88():985-990. PubMed ID: 28178630
[TBL] [Abstract][Full Text] [Related]
4. Combining Drug-Loaded Nanobubbles and Extracorporeal Shock Waves for Difficult-to-Treat Cancers.
Cavalli R; Marano F; Argenziano M; Varese A; Frairia R; Catalano MG
Curr Drug Deliv; 2018; 15(6):752-754. PubMed ID: 29046151
[No Abstract] [Full Text] [Related]
5. Targeting Taxanes to Castration-Resistant Prostate Cancer Cells by Nanobubbles and Extracorporeal Shock Waves.
Marano F; Rinella L; Argenziano M; Cavalli R; Sassi F; D'Amelio P; Battaglia A; Gontero P; Bosco O; Peluso R; Fortunati N; Frairia R; Catalano MG
PLoS One; 2016; 11(12):e0168553. PubMed ID: 28002459
[TBL] [Abstract][Full Text] [Related]
6. A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer.
Chintakuntlawar AV; Yin J; Foote RL; Kasperbauer JL; Rivera M; Asmus E; Garces NI; Janus JR; Liu M; Ma DJ; Moore EJ; Morris JC; Neben-Wittich M; Price DL; Price KA; Ryder M; Van Abel KM; Hilger C; Samb E; Bible KC
Thyroid; 2019 Nov; 29(11):1615-1622. PubMed ID: 31595822
[No Abstract] [Full Text] [Related]
7. Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.
Garg M; Kanojia D; Mayakonda A; Ganesan TS; Sadhanandhan B; Suresh S; S S; Nagare RP; Said JW; Doan NB; Ding LW; Baloglu E; Shacham S; Kauffman M; Koeffler HP
Sci Rep; 2017 Aug; 7(1):9749. PubMed ID: 28852098
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin has a synergistic cytotoxicity with cucurbitacin B in anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Tumour Biol; 2017 Feb; 39(2):1010428317692252. PubMed ID: 28218042
[TBL] [Abstract][Full Text] [Related]
9. Cell-penetrating peptide-doxorubicin conjugate loaded NGR-modified nanobubbles for ultrasound triggered drug delivery.
Lin W; Xie X; Deng J; Liu H; Chen Y; Fu X; Liu H; Yang Y
J Drug Target; 2016; 24(2):134-46. PubMed ID: 26176270
[TBL] [Abstract][Full Text] [Related]
10. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
Fallahi P; Ferrari SM; La Motta C; Materazzi G; Bocci G; Da Settimo F; Miccoli P; Antonelli A
Endocrine; 2016 Jul; 53(1):136-44. PubMed ID: 26286966
[TBL] [Abstract][Full Text] [Related]
11. Modulating tumor reactive stroma by extracorporeal shock waves to control prostate cancer progression.
Rinella L; Pizzo B; Frairia R; Delsedime L; Calleris G; Gontero P; Zunino V; Fortunati N; Arvat E; Catalano MG
Prostate; 2020 Sep; 80(13):1087-1096. PubMed ID: 32609927
[TBL] [Abstract][Full Text] [Related]
12. Anaplastic thyroid cancer.
Ranganath R; Shah MA; Shah AR
Curr Opin Endocrinol Diabetes Obes; 2015 Oct; 22(5):387-91. PubMed ID: 26313900
[TBL] [Abstract][Full Text] [Related]
13. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
Lopez JP; Wang-Rodriguez J; Chang C; Chen JS; Pardo FS; Aguilera J; Ongkeko WM
Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1022-7. PubMed ID: 17938326
[TBL] [Abstract][Full Text] [Related]
14. Small interfering RNA (siRNA) against Slug induces apoptosis and sensitizes human anaplastic thyroid carcinoma cells to doxorubicin.
Pan Y; Liu P; Chen D; Dou L
Cancer Biomark; 2017; 18(4):357-366. PubMed ID: 28128736
[TBL] [Abstract][Full Text] [Related]
15. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer.
Mehta A; Zhang L; Boufraqech M; Zhang Y; Patel D; Shen M; Kebebew E
Endocr Relat Cancer; 2015 Jun; 22(3):319-29. PubMed ID: 25972243
[TBL] [Abstract][Full Text] [Related]
16. Low intensity focused ultrasound (LIFU) triggered drug release from cetuximab-conjugated phase-changeable nanoparticles for precision theranostics against anaplastic thyroid carcinoma.
Wang Y; Sui G; Teng D; Wang Q; Qu J; Zhu L; Ran H; Wang Z; Jin C; Wang H
Biomater Sci; 2018 Dec; 7(1):196-210. PubMed ID: 30422139
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo.
Catalano MG; Pugliese M; Gargantini E; Grange C; Bussolati B; Asioli S; Bosco O; Poli R; Compagnone A; Bandino A; Mainini F; Fortunati N; Boccuzzi G
Int J Cancer; 2012 Feb; 130(3):694-704. PubMed ID: 21400508
[TBL] [Abstract][Full Text] [Related]
18. High energy shock waves activate 5'-aminolevulinic Acid and increase permeability to Paclitaxel: antitumor effects of a new combined treatment on anaplastic thyroid cancer cells.
Catalano MG; Costantino L; Fortunati N; Bosco O; Pugliese M; Boccuzzi G; Berta L; Frairia R
Thyroid; 2007 Feb; 17(2):91-9. PubMed ID: 17316109
[TBL] [Abstract][Full Text] [Related]
19. Increasing Doxorubicin Loading in Lipid-Shelled Perfluoropropane Nanobubbles
Nittayacharn P; Abenojar E; De Leon A; Wegierak D; Exner AA
Front Pharmacol; 2020; 11():644. PubMed ID: 32477125
[TBL] [Abstract][Full Text] [Related]
20. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells.
Catalano MG; Fortunati N; Pugliese M; Poli R; Bosco O; Mastrocola R; Aragno M; Boccuzzi G
J Endocrinol; 2006 Nov; 191(2):465-72. PubMed ID: 17088416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
